Journal Article DKFZ-2026-02771

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Activity of the natural biflavonoid hinokiflavone against multidrug-resistant CEM/ADR5000 leukemia cells and its modes of action via P-glycoprotein modulation.

 ;  ;  ;  ;  ;  ;  ;

2026
Elsevier München [u.a.]

Phytomedicine 162, 158883 () [10.1016/j.phymed.2026.158883]
 GO

Abstract: Multidrug resistance (MDR), frequently associated with the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), is a major obstacle to successful leukemia chemotherapy. Natural products represent an important source for anticancer drug discovery. Hinokiflavone, a natural biflavonoid, has demonstrated anticancer potential, but its underlying mechanisms against multidrug-resistant leukemia are largely unknown.We hypothesized that hinokiflavone exhibits preferential activity against P-gp-overexpressing multidrug-resistant leukemia cells through specific mechanisms associated with the multidrug-resistant phenotype.Cytotoxicity was evaluated in parental and drug-resistant cell models, and the contribution of ABCB1/P-gp to the collateral sensitivity of CEM/ADR5000 cells was investigated by siRNA-mediated ABCB1 knockdown. Molecular docking was performed to predict potential interactions with both P-gp and breast cancer resistance protein (BCRP). mRNA-based transcriptomic expression profiling, Western blot analysis, pathway analyses, and siRNA-mediated TXNIP knockdown were used to investigate signaling alterations. Intracellular ROS generation, mitochondrial membrane potential, P-gp-associated drug transport, ATP levels, cell cycle distribution, DNA damage, and apoptosis were further investigated. In addition, a zebrafish xenograft model was used to evaluate preliminary in vivo antitumor activity.Hinokiflavone exhibited collateral sensitivity toward P-gp-overexpressing CEM/ADR5000 leukemia cells, and ABCB1 knockdown markedly reduced this sensitivity. Moreover, hinokiflavone significantly restored doxorubicin sensitivity in multidrug-resistant CEM/ADR5000 cells, reducing the IC₅₀ of doxorubicin by 3.17-fold, comparable to the P-glycoprotein inhibitor verapamil. Molecular docking predicted interactions with both P-gp and BCRP. Transcriptomic and protein analyses revealed alterations in several signaling pathways (activated WNT/β-catenin signaling, increased TXNIP and PTEN expression, and reduced PI3K/AKT/mTOR signaling). TXNIP knockdown attenuated the effects of hinokiflavone on PI3K/AKT/mTOR signaling and reduced the cytotoxic response. Hinokiflavone treatment was also associated with ROS accumulation, mitochondrial membrane depolarization, altered P-gp-associated drug transport, ATP depletion, G2/M-related cell-cycle alterations, DNA damage, and apoptosis. Hinokiflavone additionally exhibited preliminary antitumor activity in an SK-N-DZ zebrafish xenograft model.Hinokiflavone exhibits collateral sensitivity in P-gp-overexpressing CEM/ADR5000 leukemia cells, with ABCB1/P-glycoprotein contributing substantially to this phenotype. Its activity is associated with oxidative stress, energy metabolism, P-gp-associated drug transport, and multiple survival signaling pathways. These findings highlight hinokiflavone's potential for targeting multidrug-resistant leukemia.

Keyword(s): CEM/ADR5000 leukemia cells ; Hinokiflavone ; Multidrug-resistant ; Natural products ; P-glycoprotein ; Zebrafish

Classification:

Note: #NCTZFB26#

Contributing Institute(s):
  1. Krebsgenomforschung (B063)
  2. Koordinierungsstelle NCT Heidelberg (HD02)
Research Program(s):
  1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2026
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2026-11-09, last modified 2026-11-10



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)